Aldeyra Therapeutics Inc ALDX:NASDAQ

Last Price$3.25NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.22(6.34%)
Bid (Size)$3.22 (1)
Ask (Size)$3.33 (2)
Day Low / High$3.24 - 3.52
Volume915.2 K

Aldeyra Therapeutics Says Reproxalap Ophthalmic Solution Achieves Primary Endpoint in Dry Eye Disease Trial

11:55AM ET 11/02/2021 MT Newswires
Aldeyra Therapeutics (ALDX) said Tuesday that a midstage clinical trial of its reproxalap ophthalmic solution in patients with dry eye disease achieved its primary endpoint of ocular redness.

The trial enlisted 158 patients and the company said the ocular redness scores of the 80 patients who received the 0.25% reproxalap ophthalmic solution "were observed to be statistically lower" than those of the subjects who received vehicle ophthalmic solution without an active compound.

Aldeyra said two phase 3 trials on reproxalap in patients with dry eye disease are ongoing, with a planned enrollment of 300 patients for each trial. According to the company, the trials' primary endpoint is ocular redness and the results are expected to be released by the end of the year.

Shares were down nearly 10% in recent trading.

Price: 8.29, Change: -0.95, Percent Change: -10.28